Antisense oligonucleotides: modifications and clinical trials

There has been an upsurge in the number of clinical trials involving chemically modified oligonucleotide-based drug candidates after the FDA approval of Vitravene, Macugen, and recently, Kynamro. Over the years, different types of backbone, nucleobase and/or sugar-modified oligonucleotides have been...

Full description

Saved in:
Bibliographic Details
Published in:MedChemComm 2014-10, Vol.5 (1), p.1454-1471
Main Authors: Sharma, Vivek K, Sharma, Raman K, Singh, Sunil K
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:There has been an upsurge in the number of clinical trials involving chemically modified oligonucleotide-based drug candidates after the FDA approval of Vitravene, Macugen, and recently, Kynamro. Over the years, different types of backbone, nucleobase and/or sugar-modified oligonucleotides have been synthesized because natural DNA/RNA based oligonucleotides pose some limitations, such as poor binding affinity, low degree of nuclease resistance, affecting their direct use in antisense therapeutics. In this review article, we discuss in detail different modifications of nucleosides/oligonucleotides along with the related clinical trials, which demonstrated their potential as drug candidates for antisense and related nucleic acid based therapeutics. Chemically modified antisense oligonucleotides have shown persistent value both in the terms of their success as approved drugs and seminal findings, leading to numerous potential drug candidates in clinical trials.
ISSN:2040-2503
2040-2511
DOI:10.1039/c4md00184b